Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks.

Uras IZ, Maurer B, Nivarthi H, Jodl P, Kollmann K, Prchal-Murphy M, Milosevic Feenstra JD, Zojer M, Lagger S, Grausenburger R, Grabner B, Holly R, Kavirayani A, Bock C, Gisslinger H, Valent P, Kralovics R, Sexl V.

Blood. 2019 Apr 11;133(15):1677-1690. doi: 10.1182/blood-2018-08-872648. Epub 2019 Jan 11.

PMID:
30635286
2.

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.

Mazzacurati L, Lambert QT, Pradhan A, Griner LN, Huszar D, Reuther GW.

Oncotarget. 2015 Nov 24;6(37):40141-57. doi: 10.18632/oncotarget.5653.

3.

Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway.

Funakoshi-Tago M, Nagata T, Tago K, Tsukada M, Tanaka K, Nakamura S, Mashino T, Kasahara T.

Cell Signal. 2012 Nov;24(11):2024-34. doi: 10.1016/j.cellsig.2012.06.014. Epub 2012 Jun 30.

PMID:
22750290
4.

JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms.

Lin CH, Kaushansky K, Zhan H.

Blood Cells Mol Dis. 2016 Nov;62:42-48. doi: 10.1016/j.bcmd.2016.09.004. Epub 2016 Nov 4.

5.

Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.

Ueda F, Tago K, Tamura H, Funakoshi-Tago M.

J Biol Chem. 2017 Feb 3;292(5):1826-1846. doi: 10.1074/jbc.M116.749465. Epub 2016 Dec 20.

6.

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.

Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.

BMC Med Genet. 2012 Jan 17;13:6. doi: 10.1186/1471-2350-13-6.

7.

Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.

Nagao T, Kurosu T, Umezawa Y, Nogami A, Oshikawa G, Tohda S, Yamamoto M, Miura O.

PLoS One. 2014 Jan 3;9(1):e84746. doi: 10.1371/journal.pone.0084746. eCollection 2014.

8.

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.

Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.

FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078. Epub 2011 Nov 3.

PMID:
22051730
9.

RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.

Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra122. doi: 10.1126/scisignal.2005301.

10.

JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.

Treliński J, Robak T.

Curr Med Chem. 2013;20(9):1147-61.

PMID:
23317159
11.

JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.

Oh ST, Gotlib J.

Expert Rev Hematol. 2010 Jun;3(3):323-37. doi: 10.1586/ehm.10.28. Review.

PMID:
21082983
12.

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R.

Sci Transl Med. 2018 Feb 21;10(429). pii: eaam7729. doi: 10.1126/scitranslmed.aam7729.

13.

JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth.

Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW.

Br J Haematol. 2013 Jan;160(2):177-87. doi: 10.1111/bjh.12103. Epub 2012 Nov 15.

14.

Hmga2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms.

Ueda K, Ikeda K, Ikezoe T, Harada-Shirado K, Ogawa K, Hashimoto Y, Sano T, Ohkawara H, Kimura S, Shichishima-Nakamura A, Nakamura Y, Shikama Y, Mori T, Mason PJ, Bessler M, Morishita S, Komatsu N, Shide K, Shimoda K, Koide S, Aoyama K, Oshima M, Iwama A, Takeishi Y.

Blood Adv. 2017 Jun 14;1(15):1001-1015. doi: 10.1182/bloodadvances.2017004457. eCollection 2017 Jun 27.

15.
16.

Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms.

Zhang SP, Li H, Lai RS.

Oncol Lett. 2015 Feb;9(2):735-738. Epub 2014 Dec 12.

17.

Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.

Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, Dirnhofer S, Tichelli A, Tzankov A.

Br J Haematol. 2009 Jul;146(2):150-7. doi: 10.1111/j.1365-2141.2009.07726.x. Epub 2009 May 19.

PMID:
19466975
18.

Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.

Lundberg P, Takizawa H, Kubovcakova L, Guo G, Hao-Shen H, Dirnhofer S, Orkin SH, Manz MG, Skoda RC.

J Exp Med. 2014 Oct 20;211(11):2213-30. doi: 10.1084/jem.20131371. Epub 2014 Oct 6.

19.

Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms

Singdong R, Siriboonpiputtana T, Chareonsirisuthigul T, Kongruang A, Limsuwanachot N, Sirirat T, Chuncharunee S, Rerkamnuaychoke B.

Asian Pac J Cancer Prev. 2016 Oct 1;17(10):4647-4653.

20.

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Teruya-Feldstein J, Murakami M, Radimerski T, Michor F, Fan R, Levine RL.

Cancer Discov. 2015 Mar;5(3):316-31. doi: 10.1158/2159-8290.CD-14-0736. Epub 2015 Jan 8.

Supplemental Content

Support Center